Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc (TSX: CRDL )

2.820 -0.010 (-0.35%)
Streaming Delayed Price Updated: 1:38 PM EDT, Jun 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 109,864
Open 2.760
Bid (Size) 2.800 (5)
Ask (Size) 2.820 (23)
Prev. Close 2.830
Today's Range 2.740 - 2.910
52wk Range 0.9100 - 4.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
Exposures Product Safety
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients 
Via News Direct
Exposures Product Safety

Performance

YTD
+136.97%
+136.97%
1 Month
-7.24%
-7.24%
3 Month
+39.60%
+39.60%
6 Month
+141.03%
+141.03%
1 Year
+110.45%
+110.45%

More News

Read More
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Via News Direct
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Via Newsfile
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Via Newsfile
Exposures Product Safety
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Via Newsfile
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
Via Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Via Newsfile
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)
Via AB Newswire
Topics Stocks
Exposures US Equities
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Via Newsfile
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
Via Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Air Pollution is a Global Heart and Lung Health Concern
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
Via FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
Via FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
Via FinancialNewsMedia
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Via FinancialNewsMedia
Topics Death
Exposures Death
Market Movers. Today’s Top Stock Picks For New & Trending Opportunities
From Stockhouse Publishing
Via AccessWire
Why Orphan Drug Designation Offers Several Benefits
Via FinancialNewsMedia
Exposures Product Safety
Heart Failure Treatment Offers Hope to Diabetics
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.